Daiichi Sankyo, a major pharmaceutical company, and KM Biologics, a pharmaceutical company in Kumamoto City, have announced that they have begun clinical trials to inoculate humans with the new coronavirus vaccine under development and confirm its safety. ..
There are now four companies conducting clinical trials with domestic vaccines.
According to Daiichi Sankyo's announcement, clinical trials will begin on the 22nd, targeting a total of 152 healthy adults and the elderly in Japan, to confirm safety and whether antibodies can be produced, as well as in Japan. It means considering the recommended dose.
The vaccine developed by Daiichi Sankyo and others uses "mRNA" that conveys the genetic information of the same virus made by Pfizer, which has already begun to be inoculated in Japan.
On the other hand, the clinical trial of KM Biologics is to target 210 healthy adults and elderly people in total, and to start inoculation on the 22nd to check the safety and whether antibodies can be produced.
KM Biologics and others are developing "inactivated" vaccines that are made by processing viruses to eliminate toxicity, and are the same type as vaccines such as seasonal influenza.
According to the Ministry of Health, Labor and Welfare, there are now four companies conducting clinical trials with domestic vaccines, in addition to the two leading companies, Shionogi and AnGes.